PureTech Health (GB:PRTC) has released an update.
Vedanta Biosciences, an entity founded by PureTech Health, has initiated the Phase 3 RESTORATiVE303 trial for their novel treatment VE303, aimed at preventing recurrent Clostridioides difficile infection (CDI). The treatment, which could be the first of its kind as a live biotherapeutic product, has shown promise in earlier trials with a substantial reduction in CDI recurrence. If successful, this trial could lead to a Biologics License Application with the FDA, indicating a significant step forward in the battle against this debilitating infection.
For further insights into GB:PRTC stock, check out TipRanks’ Stock Analysis page.
